InvestorsHub Logo
Followers 49
Posts 11680
Boards Moderated 0
Alias Born 06/15/2014

Re: None

Monday, 06/13/2022 5:49:52 AM

Monday, June 13, 2022 5:49:52 AM

Post# of 429367
I think if Amarin had found something radically wrong with the Generics’ product, they could go after them just like Ranbaxy

“Not long after Sun bought Ranbaxy from Daiichi Sankyo in 2014 the Japanese company was hit with claims against the Indian generics giant. Ranbaxy was accused of falsely representing the quality of the drugs it made as well as its handling of compliance issues raised by the FDA. By making those false assertions, they were able to be first to file and win exclusivity — giving them an opportunity to charge more for the first knockoffs.

In 2013 Ranbaxy agreed to pay $500 million — $150 million to cover a criminal fine and forfeiture with $350 million for civil claims — related to felony charges for making and selling adulterated drugs. And in 2017 Sun shelled out $150 million to cover the last of the litigation sparked by a pay-for-delay case involving Ranbaxy.”

https://endpts.com/sun-pharma-shelling-out-485m-to-settle-us-antitrust-case-against-generics-giant/